What is Leerink Partnrs’ Forecast for CLDX FY2029 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Leerink Partnrs cut their FY2029 earnings estimates for shares of Celldex Therapeutics in a research report issued on Friday, May 9th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will post earnings per share of $6.20 for the year, down from their previous forecast of $6.62. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million.

Several other equities research analysts have also recently weighed in on CLDX. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a “buy” rating and a $64.00 price target on the stock. The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Friday. Morgan Stanley reduced their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday. Finally, UBS Group lowered their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.90.

Celldex Therapeutics Stock Down 6.1%

CLDX opened at $18.33 on Monday. The stock’s 50 day moving average price is $18.99 and its two-hundred day moving average price is $22.80. The firm has a market capitalization of $1.22 billion, a P/E ratio of -7.13 and a beta of 1.39. Celldex Therapeutics has a 12-month low of $14.40 and a 12-month high of $47.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its stake in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the period. GAMMA Investing LLC raised its holdings in shares of Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 2,933 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $81,000. KBC Group NV lifted its position in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 1,647 shares during the period. Finally, AlphaQuest LLC boosted its stake in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,705 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.